W. Donnellan

发表

Examining racial differences in diffuse large B-cell lymphoma presentation and survival

C. Flowers, O. Brawley, J. Kowalski, 2013, Leukemia & lymphoma.

The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy

I. Flinn, M. Battiwalla, W. Donnellan, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

A. Logan, D. DeAngelo, M. Bishop, 2021, Blood.

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

Connie Y. C. Ma, Amit Verma, P. Greenberg, 2021, Blood advances.

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Blood.

Gamma-Delta T Cell Acute Lymphoblastic Leukemia: A Single-Center Experience

S. Mineishi, R. Paluri, W. Donnellan, 2016 .

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

A. Gershon, M. Onishi, W. Donnellan, 2022, The oncologist.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

S. Verstovsek, F. Passamonti, S. Koschmieder, 2018, Journal of Hematology & Oncology.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

P. Vyas, C. Takimoto, S. Kambhampati, 2020 .

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Connie Y. C. Ma, P. Greenberg, A. Verma, 2018, Blood.

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Journal of Clinical Oncology.

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Suzanne F. Jones, G. Fabbri, G. Borthakur, 2019, Blood.

Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML

R. Collins, S. Choe, Hua Yang, 2018, The New England journal of medicine.

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

A. Wei, S. de Botton, Sangmin Lee, 2022, The Lancet. Haematology.

Ivosidenib (AG‐120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study: AML‐221

R. Collins, S. Choe, Hua Yang, 2018, Clinical Lymphoma Myeloma and Leukemia.

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

R. Collins, K. Yen, H. Kantarjian, 2017 .

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.

S. Choe, K. Yen, H. Kantarjian, 2019, Blood.

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

P. Vyas, R. Larson, C. Takimoto, 2021 .

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Xiang Li, J. Goldberg, M. Grunwald, 2022, Clinical and translational science.

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

M. Konopleva, M. Maris, H. Kantarjian, 2016 .

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Scott E. Smith, B. Wood, M. Maris, 2016 .

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

G. Garcia-Manero, R. Paquette, M. Grunwald, 2019, Blood.

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

H. Döhner, A. Califano, M. Heuser, 2021, Leukemia & lymphoma.

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

A. Logan, M. Bishop, J. Pagel, 2019, Journal of Clinical Oncology.

Racial Disparities in Cell of Origin Among DLBCL Patients.

C. Flowers, U. Borate, L. Bernal-Mizrachi, 2012 .

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

S. Choe, K. Yen, H. Kantarjian, 2018, Blood.

Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy

J. Reeves, I. Flinn, J. Essell, 2017, British journal of haematology.

H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies.

M. Warmuth, P. Greenberg, M. Maris, 2017 .

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies

A. Fathi, M. Baer, A. Zeidan, 2023, Clinical Lymphoma Myeloma and Leukemia.

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

H. Deeg, F. Thol, P. Greenberg, 2019, Blood.

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

A. Verma, U. Borate, U. Steidl, 2018, Blood.

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

A. Fathi, M. Baer, A. Zeidan, 2017 .

Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications

G. Ramsingh, W. Donnellan, Huan Jin, 2020 .

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

J. Cortes, A. Wei, Sangmin Lee, 2019, Blood.